Search
MDxHealth SA
MDXHAdd to Watchlist
0.810USD
+0.348+75.35%
Close 08-14 16:00（ET）Quotes delayed by 15 min
77.10MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-13The current earnings forecast score of MDxHealth SA is 7.67, ranking 275 out of 387 in the Biotechnology & Medical Research industry. The average price target is 7.00, with a high of 9.00 and a low of 4.20.
Analyst Rating
Based on
6
analysts
Buy
Current Rating
2.800
Target Price
+496.25%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
MDxHealth SA
MDXH
6
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is MDxHealth SA's expected revenue for the next quarter?
MDxHealth SA's expected revenue is 25.88M.
What is MDxHealth SA's price target?
Analysts forecast that MDxHealth SA's price target is USD 7.00, with the highest forecast at USD 9.00 and the lowest forecast at USD 4.20.
How have MDxHealth SAMDXH's recent earnings per share performed?
The market expectation was USD -0.17, while MDxHealth SAMDXH's earnings per share (EPS) for the previous quarter was USD -0.17. EPS for the next quarter is expected at USD -0.19.
What is the analyst rating for MDxHealth SA?
Based on the ratings of MDxHealth SA's stock from 6 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.